Navigation Links
FDA Invests $2 Million in Partnerships Through Centers of Excellence in Regulatory Science and Innovation

SILVER SPRING, Md., Oct. 26, 2011 /PRNewswire-USNewswire/ -- The U.S. Food and Drug Administration today announced the award of $2 million to support two regional Centers of Excellence in Regulatory Science and Innovation (CERSI).


The centers, which will be located at the University of Maryland and Georgetown University, will focus on strengthening science and training needed to modernize and improve the ways drugs and medical devices are reviewed and evaluated, a major focus within the FDA.

In August 2011, the agency released the strategic plan for: "Advancing Regulatory Science at FDA" (

More recently, the agency announced a related innovation initiative, "Driving Biomedical Innovation: Initiatives for Improving Products for Patients" (

"These partnerships represent a critical, necessary and creative investment - one that will benefit not just FDA and academia, but also American consumers and industry," said FDA Chief Scientist Jesse L. Goodman, M.D., M.P.H. "The Centers of Excellence will create new scientific research, training and staff exchange opportunities for FDA and leading area institutions."

Working closely with FDA scientists, CERSI researchers will assist the FDA in driving innovation in medical product development as well as in advancing laboratory, population, behavioral, and manufacturing sciences. The agency chose to pilot the CERSIs in the Washington, D.C. area, to allow for the greatest possible face-to-face collaboration and training with FDA staff.

"These partnerships will promote faster and better scientific approaches to product development, helping people in need and supporting biotech innovation," Goodman said.

For more information:

Advancing Regulatory Science

The FDA, an agency within the U.S. Department of Health and Human Services, protects the public health by assuring the safety, effectiveness, and security of human and veterinary drugs, vaccines and other biological products for human use, and medical devices. The agency also is responsible for the safety and security of our nation's food supply, cosmetics, dietary supplements, products that give off electronic radiation, and for regulating tobacco products.

Media Inquiries: Erica Jefferson, 301-796-4988,

Consumer Inquiries: 888-INFO-FDA   

SOURCE U.S. Food and Drug Administration
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. First Advantage Invests in Workstream Inc.
2. Amcor Invests €6.7 Million in the Extension of its Singen Converting Plant in Germany
3. Foundation Venture Capital Group Invests in Company Developing Plaque-Reducing Dental Hygiene Products
4. Eli Lilly and Company Invests $2.5 Million to Launch The Mind Trusts Grow What Works Campaign
5. JumpStart Ventures Invests in Cleveland-based SPR Therapeutics
6. JumpStart Ventures Invests In and Provides Entrepreneurial Assistance to Drug Development Company
7. University of Michigan Wolverine Venture Fund Invests in Delphinus Medical Technologies
8. The SCOOTER Store Invests in Ethics Training for Future Doctors
9. Foundation Venture Capital Group Invests in Start-Up Company Developing Blood Test to Determine Risk and Diagnose Alzheimers Disease
10. Dutch Public-Private Partnership Invests 28 Million Euro on Research Into Personalized Medicine
11. JumpStart Invests in Checkpoint Surgical
Post Your Comments:
(Date:12/1/2015)... --  MabVax Therapeutics Holdings, Inc . (OTCQB: MBVX), a ... an Investigational New Drug Application (IND) with the U.S. ... fully human antibody product HuMab 5B1 as a therapeutic ... the Phase I clinical trial early in 2016. ... planned Phase I trial will evaluate the safety, tolerability ...
(Date:12/1/2015)... 2015  Booth #3506 – Claymount is featuring its full ... of the Radiological Society of North America ... Based in the Netherlands , Claymount is ... (NYSE: VAR ) and is one of the world,s ... state automatic exposure control systems for controlling dose during medical ...
(Date:12/1/2015)... , Dec. 1, 2015  Lexicon Pharmaceuticals, ... that top-line data from its TELECAST Phase ... in treating carcinoid syndrome in cancer patients ... clinical benefit observed in its pivotal TELESTAR ... a companion to TELESTAR primarily to provide ...
Breaking Medicine Technology:
(Date:12/1/2015)... NY (PRWEB) , ... December 01, 2015 , ... ... in the 1980s we have seen vast improvements in scientific research and discoveries, ... significant strides, providing increased hope and relief to those affected by HIV/AIDS. Mediaplanet’s ...
(Date:12/1/2015)... New York, NY (PRWEB) , ... December 01, ... ... cause of non-traumatic limb amputations in the United States. Podiatrists are well aware ... (failure to adopt therapeutic behaviors) are often catastrophic contributors to diseases of the ...
(Date:12/1/2015)... ... December 01, 2015 , ... ... Imaging Inc. (“Visage”), a wholly owned subsidiary of Pro Medicus Ltd. (ASX: PME), ... at the Radiological Society of North America (RSNA) 2015 annual meeting through December ...
(Date:12/1/2015)... ... December 01, 2015 , ... Lutronic, a leading innovator of aesthetic and ... to the devices for sale in the United States. Clarity is a Superior ... nm Nd:YAG lasers, into a single platform that is easy to own and operate. ...
(Date:12/1/2015)... ... December 01, 2015 , ... ... and SACC-USA through membership and leadership since 2008. Gary Bruce, President of PartnerTech ... . Gary has spent a significant amount of time in Sweden since joining ...
Breaking Medicine News(10 mins):